Polypid Ltd. (PYPD) Ori Warshavsky COO.

An innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid's lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections.

All Episodes Previous Episode

Listen for free

RSS Feed Apple Podcasts Spotify Pocket Casts

About the Podcast

The Wall Street Resource

Your resource for microcap discovery and due diligence

As part of the investment process, we have conducted countless CEO and executive interviews, and found this to be an invaluable use of time. We provide The Wall Street Resource, not only to help you leverage your time, but for discovery and a starting point for due diligence.

About your host

Jeffrey Kone

Managing Member and portfolio manager of a micro-cap fund for over 15 years. Securities experience that encompasses almost all aspects of the industry (buy side, sell side, retail, institutional and investment banking). Degree from University of Southern California with a Bachelor of Science in Business, emphasis in Entrepreneurship.